PLK1 and cancer: Clinical trials of early PLK1 inhibitors in cancers were disappointing, although the newer inhibitor Volasertib showed encouraging results in combination with cytarabine in leukemia33, suggesting that PLK1 inhibitors may be more effective in a combination setting.